UBS downgraded shares of Carl Zeiss Meditec to 'Sell' from 'Neutral' on Monday, citing concerns over weakening demand in the company's core ophthalmology and microscopy businesses.
The Swiss bank also lowered its price target for the German medical technology firm to €22.60 from €25.00, reflecting a 9.6% reduction. The move follows a broader reassessment of growth prospects in the sector, according to UBS analysts.
The downgrade comes amid growing caution among investors regarding medical technology companies, particularly those exposed to elective procedures and capital equipment spending. Carl Zeiss Meditec, a leading provider of ophthalmic and surgical microscopes, has faced headwinds from reduced hospital budgets and slower adoption of advanced imaging systems.
UBS's decision aligns with a mixed outlook for the sector, where demand for high-end medical devices remains uneven. While some segments, such as digital health and AI-driven diagnostics, continue to expand, traditional equipment providers are grappling with pricing pressures and delayed purchasing decisions.
The downgrade follows similar actions by other major banks. Barclays recently adjusted its stance on Carl Zeiss Meditec, though details of its revision were not immediately available. The broader market sentiment for medical technology stocks has also softened, with concerns over economic uncertainty and healthcare spending weighing on valuations.
Carl Zeiss Meditec's shares have underperformed the broader German market this year, reflecting investor skepticism about near-term growth. The company is scheduled to report its next quarterly earnings on October 24, with analysts expecting a modest decline in revenue compared to the prior year.
UBS's downgrade underscores the challenges facing medical technology firms as they navigate a post-pandemic landscape marked by cost-cutting measures and shifting priorities in healthcare systems worldwide.
